Progyny, Inc. (PGNY)

Progyny's stock price has experienced a significant downturn, reaching a new 52-week low in April 2026. Several analysts have lowered their price targets for Progyny. Its fiscal year 2026 guidance fell below Wall Street expectations, impacting headline growth projections for 2026. Additionally, insider selling has also been noted.

Demand for Progyny's products and services exhibits some seasonality. The company's "selling season" materially influences annual intake and utilization rates. Covered lives and utilization are identified as primary volume drivers each January plan year. Progyny's growth strategy includes expanding into product adjacencies to increase addressable spend per member and to help smooth out utilization seasonality.

Progyny, Inc. specializes in fertility and family building solutions within the United States, operating in the Managed Healthcare sector. Its core business revolves around its proprietary "Smart Cycle" approach, providing comprehensive fertility benefits and access to advanced technology. Progyny offers an integrated pharmacy benefits solution called Progyny Rx, providing members with access to necessary fertility medications, care management services, and pharmacy support. The company has expanded its offerings to include broader women's health services and serves a diverse clientele of employers across various industries.

Progyny's primary geographic market is the United States, where it maintains a provider network across all 50 states. The company has a concentrated market share in major metropolitan areas, including New York City, San Francisco, Boston, and Chicago. Progyny has seen accelerated expansion into Sun Belt states like Texas and Florida, driven by corporate relocations. While Progyny has a Global Provider Network that supports operations in the UK, Canada, and select EU offices, the U.S. market accounts for over 95% of its total revenue. The company's headquarters are located in New York, NY.

Progyny has cultivated a strong brand reputation, evidenced by numerous accolades over the past year and a client retention rate of approximately 99%. However, the loss of a significant client like Amazon in 2024 could be perceived as an event impacting its reputation. Progyny is subject to the risk of negative publicity, which could adversely affect its business and reputation.

Progyny's ownership is predominantly institutional, with these entities holding approximately 95% of the outstanding shares. Major institutional shareholders include BlackRock, Inc., Vanguard Group Inc, Fmr Llc, State Street Corp, Ameriprise Financial Inc, Wellington Management Group Llp, Citadel Advisors Llc, Geode Capital Management, Llc, Thrivent Financial For Lutherans, and Fort Washington Investment Advisors Inc /oh/. Insider ownership, including stakes held by the CEO and executive chair, is modest, typically around 2-3%.